Biogen’s Alzheimer’s drug is unlikely to win E.U. approval.

The drug, Aduhelm, has been mired in controversy since it was in approved in the United States in June.The drug, Aduhelm, has been mired in controversy since it was in approved in the United States in June.Aduhelm (Drug), Drugs (Pharmaceuticals), Alzheimer’s Disease, Biogen Inc, Europe, Medicare, European Medicines AgencyRead More

Leave a Reply

Your email address will not be published.